Mercaptor Tackles Neurodegenerative Diseases
Unconventional, Unexpected and Unbiased
NOVATO, Calif., May 2, 2017 /PRNewswire/ -- Mercaptor Discoveries Inc. (Mercaptor) debuts with a devotion to scientific enquiry, a faith in its singular ability to change the world and experience traveling the roads from bench to clinic. We occupy a niche, early drug-development, largely avoided by "Big Pharma". The brainchild of industry veterans Sara Isbell (CEO), Todd Zankel (CSO) and Kim Tsuchimoto (CFO), Mercaptor was conceived to pursue a 2016 discovery offering a new approach to the management of intractable CNS disorders.
"We are taking responsibility for the development of a left-field discovery that inspires unique conceptual solutions to particular CNS diseases," said Sara Isbell, Mercaptor's CEO and President. Mercaptor is developing novel small-molecules with unusual characteristics and evident potential for people with brain trauma and neurodegeneration.
Mercaptor has licensed intellectual property covering compositions and methods for the treatment of neurological disorders like stroke, chronic traumatic encephalopathy (CTE), amyotrophic lateral sclerosis (ALS), epilepsy, Parkinson's and Alzheimer's diseases. CTE and ALS have recently garnered increased attention as former NFL players raise public awareness about the consequences of repeated, sub-acute brain trauma. Mercaptor's injury-activated technology carries equal promise for both acute and recurring brain trauma, prevalent amongst athletes and military veterans alike.
With a lean business model and wariness for convention, Mercaptor aims to bring real change to the practice of medicine in the neurology clinic. "We are a small company with big ideas. We have the flexibility to follow the data, driving new science further and faster, by avoiding the bloated process hurdles found at larger companies. Science benefits patients more than marketing. Truth is fundamental to everything that we do," Isbell explains.
About Mercaptor Discoveries
Mercaptor Discoveries is a privately held company that was founded in October 2016 by a team of scientists who had stumbled onto some interesting structure-activity relationships with clear potential. Rather than let the discovery languish for absence of a path-to-sales within a year, they took a leap of faith and became a self-seeded enterprise with a clear goal: Limiting pathologies associated with Alzheimer's disease, ALS, chronic traumatic encephalopathy, Parkinson's disease, stroke, epilepsy and other debilitating conditions in animals and man. Headquartered in Novato, California, Mercaptor prioritizes science, promotes productivity and transparency, and values the purity of research.
SOURCE Mercaptor Discoveries Inc.
Share this article